{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:44:42Z","timestamp":1788216282191,"version":"build-2803163510"},"reference-count":24,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2022,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the prevalence of dry eye disease (DED) after cataract surgery, and the impact of hyaluronic acid and ginkgo biloba eyedrops (HA-GB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Forty patients with no DED received Ocular Surface Disease Index (OSDI) questionnaire, assessment of conjunctival hyperemia and epithelial damage, fluorescein tear break-up time (TBUT) at baseline, day 1, week 1, and 4; adherence and tolerability were checked at weeks 1 and 4. At day 0 patients underwent cataract surgery and were randomized to standard postoperative care (control group) or standard postoperative care + HA-GB 3 times a day for 4 weeks (HA-GB group).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At baseline, TBUT was 9.6\u2009\u00b1\u20092.6 sec in controls and 9.0\u2009\u00b1\u20091.6 in HA-GB; thereafter it was higher in HA-GB group: 5.8\u2009\u00b1\u20092.3 versus 7.8\u2009\u00b1\u20093.2 (week 1,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.03) and 6.4\u2009\u00b1\u20092.3 versus 8.5\u2009\u00b1\u20092.5 (week 4,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.009). OSDI and conjunctival hyperemia were better in HA-GB group at week 4; respectively, 9.0\u2009\u00b1\u20095.7 versus 14.8\u2009\u00b1\u20097.3 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.004) and 5% versus 35% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.04). In the last 2 visits 50% of controls were symptomatic (OSDI of 13 or higher) compared with 16% on HA-GB group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001). In addition, tolerability was higher in HA-GB group (week 1: 0.81\u2009\u00b1\u20090.20 versus 0.70\u2009\u00b1\u20090.24,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.007; week 4: 0.93\u2009\u00b1\u20090.17 versus 0.80\u2009\u00b1\u20090.28,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Treatment with HA-GB is effective in reducing DED signs and symptoms in patients receiving cataract surgery, with high tolerability and safety profiles.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link>\n                      (ID number NCT05002036).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2021.0123","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T15:19:18Z","timestamp":1650467958000},"page":"305-310","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinical Efficacy of an Eyedrop Containing Hyaluronic Acid and Ginkgo Biloba in the Management of Dry Eye Disease Induced by Cataract Surgery"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8183-5365","authenticated-orcid":false,"given":"Paolo","family":"Fogagnolo","sequence":"first","affiliation":[{"name":"Eye Clinic, ASST Santi Paolo e Carlo, Universit\u00e0 degli Studi, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Romano","sequence":"additional","affiliation":[{"name":"Eye Clinic, ASST Santi Paolo e Carlo, Universit\u00e0 degli Studi, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"De Ruvo","sequence":"additional","affiliation":[{"name":"Eye Clinic, ASST Santi Paolo e Carlo, Universit\u00e0 degli Studi, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfilippo","family":"Sabella","sequence":"additional","affiliation":[{"name":"Eye Clinic, ASST Santi Paolo e Carlo, Universit\u00e0 degli Studi, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Rossetti","sequence":"additional","affiliation":[{"name":"Eye Clinic, ASST Santi Paolo e Carlo, Universit\u00e0 degli Studi, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.09.008"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70081-2"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.004"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.06.016"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078657"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.006"},{"key":"e_1_3_6_8_2","author":"Schiffman R.M.","unstructured":"Schiffman R.M., , Christianson M.D., , Jacobsen G., , Hirsch J.D., , and Reis B.L. Reliability and validity of the ocular surface disease index. Arch. Ophthalmol.118:615\u2013621, 2000.","journal-title":"Arch. Ophthalmol"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1475-1313.1999.00420.x-i1"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.001"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0048"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S74849"},{"key":"e_1_3_6_13_2","author":"Iester M.","unstructured":"Iester M., , Oddone F., , Fogagnolo P., , Frezzotti P., , Figus M; Confocal Microscopy Study Group. Changes in the morphological and functional patterns of the ocular surface in patients treated with prostaglandin analogues after the use of TSP 0.5%\u00ae preservative-free eyedrops: a prospective, multicenter study. Ophthalmic. Res.51:146\u2013152, 2014.","journal-title":"Ophthalmic. Res"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006324-200206000-00009"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23746"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-0717-8_157"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-695"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000342196"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01288-z"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88589-7"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S264520"},{"key":"e_1_3_6_22_2","first-page":"601","article-title":"What is Ginkgo biloba extract EGb 761?","volume":"48","author":"Christen Y.","year":"2002","unstructured":"Christen Y., , and Maixent J.M. What is Ginkgo biloba extract EGb 761?. An overview\u2014from molecular biology to clinical medicine. Cell. Mol. Biol (Noisy-le-grand)., 48:601\u2013611, 2002.","journal-title":"An overview\u2014from molecular biology to clinical medicine. Cell. Mol. Biol (Noisy-le-grand)."},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-4887.2008.00078.x"},{"key":"e_1_3_6_24_2","author":"Thiagarajan G.","unstructured":"Thiagarajan G., , Chandani S., , Harinarayana Rao S., et al. Molecular and cellular assessment of ginkgo biloba extract as a possible ophthalmic drug. Exp. Eye. Res. 75:421\u2013430, 2002. PMID: 12387790.","journal-title":"Exp. Eye. Res"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067210901900301"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2021.0123","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2021.0123","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2021.0123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:44:55Z","timestamp":1777646695000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2021.0123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,5,1]]}},"alternative-id":["10.1089\/jop.2021.0123"],"URL":"https:\/\/doi.org\/10.1089\/jop.2021.0123","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,1]]}}}